scholarly journals Surgical Remission of Acromegaly Resolves Neuroglycopenia and Paradoxical Rise in GH after OGTT

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A613-A613
Author(s):  
Maria Magar ◽  
John Carmichael

Abstract Background: Acromegaly is known to cause insulin resistance through increased gluconeogenesis and reduction in peripheral glucose use; however, hypoglycemia related to acromegaly has not been reported. Clinical Case: A 58-year old man presented for evaluation of several elevated serum IGF1 levels. The patient had reported years of increased body heat but no changes in his hands or feet and no voice deepening. He recently needed 15 dental crowns due to gaps in his teeth. He also had difficult to manage OSA and weight gain. The patient reported neuroglycopenia after a high glycemic meal or drink, although he was never able to objectively measure any low blood glucoses when they occurred; these symptoms improved but did not resolve despite adhering to a low carbohydrate diet. He also had decreased libido and erectile dysfunction. Exam was significant for coarse facial features. Prior testing revealed several elevated IGF1 serum levels, the last one being 227 ng/mL (54-194). One year prior, OGTT resulted in an initial GH level of 0.1 ng/mL with a decrease to <0.1 ng/mL after two hours. Repeat OGTT had an initial GH of 2.98 ng/mL which paradoxically rose to 12 ng/mL. Fasting BG was 90 mg/dL and peaked at 171 mg/dL. Pituitary MRI showed a 5 mm microadenoma, consistent with acromegaly from a GH secreting adenoma. He underwent a TSSC, and his heat intolerance, low libido, and symptom of hypoglycemia resolved completely. Subsequent IGF1 levels and MRI imaging normalized. Postoperatively OGTT showed a peak GH of 0.23 ng/mL with a peak glucose of 134 mg/dL. There was no paradoxical rise in GH. Discussion: Acromegaly is commonly associated with insulin resistance in ~30% of cases; however, there are no reports of associated neuroglycopenia after a carbohydrate-rich meal or OGTT, which in our patient resolved after successful removal of the pituitary microadenoma. His low glucose symptoms could have been a result of reactive hypoglycemia, which is often seen in patients with diabetes or even prediabetes. However this patient had no history of either. He did not have evidence of any tumors causing hypoglycemia and no gastric surgery to suggest a related etiology (e.g, dumping syndrome or nesidioblastosis). Conversely since GH is normally anabolic and stimulates insulin release, the patient’s elevated GH may have caused an abnormal increase in insulin, leading to his hypoglycemia symptoms. Indeed GIP, which stimulates insulin, is thought to be the cause of the paradoxical rise in GH seen in 30% of acromegaly cases. Remarkably, the patient’s hypoglycemia symptoms disappeared after treatment of the acromegaly, which leads us to consider that excess GH was the culprit.

2020 ◽  
Author(s):  
Yun Chen ◽  
Sayantana Das ◽  
Guangchao Zhuo ◽  
Hong Cai

Abstract Background Galectin-3 binding protein (GAL-3BP) is one of the major fucosylated glycoprotein family members, and is implicated in nonalcoholic fatty liver disease, lipid dysfunctions and coronary artery disease recently. Here we analyzed the serum concentrations of GAL-3BP in postmenopausal women, to evaluate the association of circulating GAL-3BP and insulin resistance in female after menopause. Method We evaluated serum levels of Gal-3BP in sixty-two non-diabetic women in menopausal status for at least one year. The clinical features, biochemistry profiles and homeostasis model assessment of insulin resistance (HOMA-IR) were obtained routinely. Results Gal-3BP levels increased in women with higher HOMA-IR values and was positively correlated to HOMA-IR. It was also an independent risk factors for HOMA-IR and showed the most influence on HOMA-IR comparing to FPG, TG, age and BMI. The cut-off value of serum Gal-3BP level was 2234.3150 ng/ml with the area under the ROC curve (AUC) 0.68 (HOMA-IR 1.5), 0.81 (HOMA-IR 2.0) and 0.93 (HOMA-IR 2.5). Conclusions Serum levels of Gal-3BP is associated with impaired insulin sensitivity in non-diabetic menopausal women.


2019 ◽  
Vol 160 (25) ◽  
pp. 973-979
Author(s):  
Bíborka Nádró ◽  
Ferenc Sztanek ◽  
Hajnalka Lőrincz ◽  
Dénes Páll ◽  
György Paragh ◽  
...  

Abstract: Progranulin is a recently recognized multifunctional glycopeptide shown to be related to obesity and diabetes mellitus. Progranulin is an endogenous antagonist of tumor necrosis factor-α by competitively binding to its receptor, therefore, it exerts anti-inflammatory activity. Paradoxically, previous studies have shown that serum levels of progranulin were elevated in patients with diabetes and associated to its complications including micro- and macroangiopathies, macroalbuminuria or reduced renal function. Moreover, hyperprogranulinemia may be involved in the pathogenesis of obesity-associated insulin resistance. The review summarizes the currently available data on progranulin as a novel marker of the carbohydrate metabolism and inflammation. Orv Hetil. 2019; 160(25): 973–979.


Scientifica ◽  
2016 ◽  
Vol 2016 ◽  
pp. 1-9
Author(s):  
Mervat Y. Hanafi ◽  
Mohamed I. Saad ◽  
Taha M. Abdelkhalek ◽  
Moustafa M. Saleh ◽  
Maher A. Kamel

Background. Intrauterine environment plays a pivotal role in the origin of fatal diseases such as diabetes. Diabetes and obesity are associated with low-grade inflammatory state and dysregulated adipokines production. This study aims to investigate the effect of maternal obesity and malnutrition on adipokines production (adiponectin, leptin, and TNF-α) in F1 offspring in rats.Materials and Methods. Wistar rats were allocated in groups: F1 offspring of control mothers under control diet (CF1-CD) and under high-fat diet (CF1-HCD), F1 offspring of obese mothers under CD (OF1-CD) and under HCD (OF1-HCD), and F1 offspring of malnourished mothers under CD (MF1-CD) and under HCD (MF1-HCD). Every 5 weeks postnatally, blood samples were obtained for biochemical analysis.Results. At the end of the 30-week follow-up, OF1-HCD and MF1-HCD exhibited hyperinsulinemia, moderate dyslipidemia, insulin resistance, and impaired glucose homeostasis compared to CF1-CD and CF1-HCD. OF1-HCD and MF1-HCD demonstrated low serum levels of adiponectin and high levels of leptin compared to CF1-CD and CF1-HCD. OF1-CD, OF1-HCD, and MF1-HCD had elevated serum levels of TNF-αcompared to CF1-CD and CF1-HCD (p<0.05).Conclusion. Maternal nutritional manipulation predisposes the offspring to development of insulin resistance in their adult life, probably via instigating dysregulated adipokines production.


2019 ◽  
Author(s):  
Sofija Davidović ◽  
Babić Nikola ◽  
Jovanović Sandra ◽  
Barišić Sava ◽  
Grković Desanka ◽  
...  

Abstract Erythropoietin (EPO) is one of the systemic angiogenic factors, and its role in ocular angiogenesis and in diabetic retinopathy (DR) is not yet fully understood. The latest research data reveal a possible correlation of higher erythropoietin concentrations in the blood and in the eye with the development of more advanced stages of DR. The main aim of this work was to examine the possible influence of serum concentrations of erythropoietin on the development of diabetic retinopathy in patients with diabetes mellitus type 2.Methods The research involved 90 patients examined at the University Eye Clinic of the Clinical Center of Vojvodina, Novi Sad, Serbia. The first group comprised 60 patients with diabetes mellitus lasting for ten years or more, with diabetic retinopathy. The second, control group consisted of 30 healthy individuals. In the first group of 60 patients with diabetes, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR). Laboratory EPO serum levels were determined, and they were correlated to the stage of DR. Concentration of EPO was assessed by ELISA method.Results The highest average concentration of EPO in serum (9.95 mIU/ml) was determined in the group of people with diabetes with PDR. The lowest average concentration of EPO in the serum (6.90 mIU/ml) was found in the control group. The average concentration of EPO in serum in the group of patients with diabetes with NPDR was 7.00 mIU/ml. The EPO concentration in serum was elevated in the group of PDR, and it was directly proportional to the level of the clinical stadium of PDR, being significantly higher in the moderate and severe subgroup of PDR comparing to the control healthy subjects, NPDR and mild PDR (p=0.007).Conclusions Significantly elevated serum concentration of EPO in the advanced stages of DR, and positive correlation between EPO serum concentration and clinical stages of PDR, suggest that erythropoietin represents an important growth factor from blood, which plays a significant role in retinal ischemia and angiogenesis in diabetic retinopathy, especially in the proliferative stage of this disease.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Sofija Davidović ◽  
Nikola Babić ◽  
Sandra Jovanović ◽  
Sava Barišić ◽  
Desanka Grković ◽  
...  

Abstract Background Erythropoietin (EPO) is one of the systemic angiogenic factors, and its role in ocular angiogenesis and in diabetic retinopathy (DR) is not yet fully understood. The latest research data reveal a possible correlation of higher erythropoietin concentrations in the blood and in the eye with the development of more advanced stages of DR. The main aim of this work was to examine the possible influence of serum concentrations of erythropoietin on the development of diabetic retinopathy in patients with diabetes mellitus type 2. Methods The research involved 90 patients examined at the University Eye Clinic of the Clinical Center of Vojvodina, Novi Sad, Serbia. The first group comprised 60 patients with diabetes mellitus lasting for 10 years or more, with diabetic retinopathy. The second, control group consisted of 30 healthy individuals. In the first group of 60 patients with diabetes, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR). Laboratory EPO serum levels were determined, and they were correlated to the stage of DR. Concentration of EPO was assessed by ELISA method. Results The highest average concentration of EPO in serum (9.95 mIU/ml) was determined in the group of people with diabetes with PDR. The lowest average concentration of EPO in the serum (6.90 mIU/ml) was found in the control group. The average concentration of EPO in serum in the group of patients with diabetes with NPDR was 7.00 mIU/ml. The EPO concentration in serum was elevated in the group of PDR, and it was directly proportional to the level of the clinical stadium of PDR, being significantly higher in the moderate and severe subgroup of PDR comparing to the control healthy subjects, NPDR and mild PDR (p = 0.007). Conclusions Significantly elevated serum concentration of EPO in the advanced stages of DR, and positive correlation between EPO serum concentration and clinical stages of PDR, suggest that erythropoietin represents an important growth factor from blood, which plays a significant role in retinal ischemia and angiogenesis in diabetic retinopathy, especially in the proliferative stage of this disease.


Endocrine ◽  
2006 ◽  
Vol 29 (3) ◽  
pp. 419-424 ◽  
Author(s):  
Yi-fei Zhang ◽  
Yi-sheng Yang ◽  
Jie Hong ◽  
Wei-qiong Gu ◽  
Chun-fang Shen ◽  
...  

2021 ◽  
Author(s):  
Hamad Ali ◽  
Mohamed Abu-Farha ◽  
Eman Alshawaf ◽  
Sriraman Devarajan ◽  
Yousif Bahbahani ◽  
...  

Abstract Background: Diabetic nephropathy (DN) is a kidney-related complication affecting approximately 40% of patients with diabetes. Current DN diagnostic criteria predominantly rely on albuminuria and serum creatinine levels; however, the specificity and reliability of both markers are limited. Hence, reliable biomarkers are required to diagnose and effectively manage DN progression. Methods: Here we investigated the expression level and the association between neutrophil gelatinase-associated lipocalin (NGAL), IGFBP-1, IGFBP-3, and IGFBP-4 in patients with DN and compared it to patients with T2D and control participants. A cohort comprise of 159 individuals (DN = 67) was clinically evaluated and circulatory levels of NGAL, IGFBP1, IGFBP3, and IGFBP4 were determined using ELISA. Results: Levels of circulating NGAL were significantly higher in people with DN compared to people with T2D and non-diabetic groups (92.76 ± 7.5, 57.22 ± 8.7, and 52.47 ± 2.9 mg/L, respectively; p < 0.0001). IGFBP4 showed a similar pattern, where it was highest in people with DN (795.61 ng/ml ±130.7) compared to people with T2D and non-diabetic respectively (374.56 ng/ml ±86.8, 273.06 ng/ml ±27.8, ANOVA p<0.01). Our analysis presents a significant positive correlation between NGAL and IGFBP4 in people with DN (ρ =.620, p <0.005). IGFBP4 also correlated positively with creatinine level and negatively with eGFR, in people with DN supporting its involvement in DN. Conclusion: Our results report the association between the rise in NGAL and IGFBP4 levels in DN and suggest them as potential markers to aid DN diagnosis.


Endocrinology ◽  
2009 ◽  
Vol 150 (2) ◽  
pp. 625-633 ◽  
Author(s):  
Aimin Xu ◽  
Hongbing Wang ◽  
Ruby L. C. Hoo ◽  
Gary Sweeney ◽  
Paul. M. Vanhoutte ◽  
...  

Adiponectin is an adipocyte-derived insulin-sensitizing hormone with antidiabetic, antiinflammatory, and antiatherosclerotic properties. A decreased serum level of adiponectin in obesity has been identified as an independent risk factor for diabetes and cardiovascular complications, suggesting that pharmacological intervention aimed at elevating adiponectin production might hold promise for the treatment and/or prevention of these diseases. Here we report the identification of two structurally related natural compounds (astragaloside II and isoastragaloside I) from the medicinal herb Radix Astragali that possess such an activity. Astragaloside II and isoastragaloside I selectively increased adiponectin secretion in primary adipocytes without any obvious effects on a panel of other adipokines. Furthermore, an additive effect on induction of adiponectin production was observed between these two compounds and rosiglitazone, a thiazolidinedione class of insulin-sensitizing drugs. Chronic administration of astragaloside II and isoastragaloside I in both dietary and genetic obese mice significantly elevated serum levels of total adiponectin and selectively increased the composition of its high molecular weight oligomeric complex. These changes were associated with an alleviation of hyperglycemia, glucose intolerance, and insulin resistance. By contrast, the beneficial effects of these two compounds on insulin sensitivity and glucose metabolism were diminished in adiponectin knockout mice. In conclusion, our results suggest that pharmacological elevation of circulating adiponectin alone is sufficient to ameliorate insulin resistance and diabetes and support the use of adiponectin as a biomarker for future drug discovery. The two natural compounds might provide the lead as a novel class of therapeutics for obesity-related diseases. Natural compounds alleviate insulin resistance by inducing adiponectin production.


Sign in / Sign up

Export Citation Format

Share Document